Fukuoka, Kurume, Japan Clinical Trials

A listing of Fukuoka, Kurume, Japan clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 75 clinical trials
A Study of TAK-994 in Adults With Narcolepsy

Adults with narcolepsy who have completed the TAK-994-1501 study will be able to take part in this study. The main aim of this study is to check if participants have side effects from TAK-994. Participants will take one of 3 different TAK-994 dose for 8 weeks. Then, half the participants …

Kurume University Hospital,Dept of Neuropsychiatry
 (0.6 away) Contact site
  • 8 views
  • 07 Jul, 2021
  • +151 other locations
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in patients with metastatic non small-cell lung cancer …

Research Site
 (0.6 away) Contact site
  • 712 views
  • 04 Jun, 2021
  • +148 other locations
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the …

EGFR
growth factor
pemetrexed
HER2
cancer chemotherapy
Kurume University Hospital
 (0.6 away) Contact site
  • 0 views
  • 31 May, 2021
  • +97 other locations
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Ulcerative Colitis

This phase 2b study is designed to have all subjects go into a 12 week induction period to compare different doses of study drug against placebo. After induction is complete all subjects will receive active therapy for 40 weeks, followed by a 12 week follow up period.

Kurume University Hospital
 (0.6 away) Contact site
  • 32 views
  • 01 Aug, 2021
  • +248 other locations
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of targeting different pathways known to be involved in the pathogenesis of the disease. Adherence to prescribed therapy has an impact on clinical outcomes. Reducing the pill/tablet count …

Kurume University Hospital
 (0.6 away) Contact site
  • 100 views
  • 17 Jul, 2021
  • +219 other locations
SAR408701 Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients

Primary Objectives: Study is designed with two primary endpoints that will be analyzed on randomized participants at the time of the cutoff date for each given analysis (progressive free survival [PFS] and overall survival [OS]). Study success is defined either on PFS or OS The primary objective is to determine …

docetaxel
platinum-based chemotherapy
measurable disease
cancer
squamous non-small cell lung cancer
Investigational Site Number 3920008
 (0.0 away) Contact site
  • 23 views
  • 18 Apr, 2021
  • +217 other locations
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy

The primary objectives of this study are to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with SMA, as measured by change in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) total score (Part B); to examine the safety and tolerability of …

gene deletion
muscle atrophy
nusinersen
Kurume University Hospital
 (0.6 away) Contact site
  • 42 views
  • 01 Aug, 2021
  • +46 other locations
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.

left ventricular end-diastolic pressure
ventricular septal defect
septal defect
heart disease
connective tissue disease
Kurume University Hospital
 (0.6 away) Contact site
  • 56 views
  • 16 Jul, 2021
  • +265 other locations
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).

EGFR
solid tumour
growth factor
cancer treatment
lung carcinoma
Kurume University Hospital
 (0.6 away) Contact site
  • 27 views
  • 02 Aug, 2021
  • +325 other locations
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared With Carboplatin-Pemetrexed in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.

EGFR
growth factor
carboplatin
pemetrexed
lung carcinoma
Kurume University Hospital
 (0.6 away) Contact site
  • 0 views
  • 29 Jul, 2021
  • +281 other locations